NCT02532686View on ClinicalTrials.gov

DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Schizophrenia
Interventions
DRUG

DAAOI-2

500-2000mg/d, oral, for 6 weeks

DRUG

placebo

oral, for 6 weeks

Trial Locations (1)

Unknown

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

China Medical University Hospital

OTHER

NCT02532686 - DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia | Biotech Hunter | Biotech Hunter